1 |
MAPK14
| 35件: MAPK signaling pathway MAPK signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09639
D09639
|
Losmapimod
| 2件: 113 113, 222 |
2 |
MAPK14
| 35件: MAPK signaling pathway MAPK signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D10959
D10959
|
Neflamapimod
| 1件: 8 8 |
3 |
IFNA1
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
4 |
IFNA1
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
5 |
IFNA2
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
6 |
IFNA2
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
7 |
IFNA4
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
8 |
IFNA4
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
9 |
IFNA5
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
10 |
IFNA5
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
11 |
IFNA6
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
12 |
IFNA6
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
13 |
IFNA7
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
14 |
IFNA7
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
15 |
IFNA8
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
16 |
IFNA8
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
17 |
IFNA10
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
18 |
IFNA10
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
19 |
IFNA13
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
20 |
IFNA13
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
21 |
IFNA14
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
22 |
IFNA14
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
23 |
IFNA16
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
24 |
IFNA16
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
25 |
IFNA17
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
26 |
IFNA17
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
27 |
IFNA21
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
28 |
IFNA21
| 10件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
29 |
IL1B
| 22件: MAPK signaling pathway MAPK signaling pathway, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Malaria, Tuberculosis, Measles, Rheumatoid arthritis, Lipid and atherosclerosis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
30 |
IL1B
| 22件: MAPK signaling pathway MAPK signaling pathway, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Malaria, Tuberculosis, Measles, Rheumatoid arthritis, Lipid and atherosclerosis | D06635
D06635
|
Rilonacept
| 4件: 51 51, 106, 107, 266 |
31 |
IL1B
| 22件: MAPK signaling pathway MAPK signaling pathway, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Malaria, Tuberculosis, Measles, Rheumatoid arthritis, Lipid and atherosclerosis | D09315
D09315
|
Canakinumab
| 10件: 46 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 |
32 |
IL1B
| 22件: MAPK signaling pathway MAPK signaling pathway, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Malaria, Tuberculosis, Measles, Rheumatoid arthritis, Lipid and atherosclerosis | D09911
D09911
|
Gevokizumab
| 4件: 41 41, 50, 56, 269 |
33 |
IL6
| 20件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Malaria, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis, Lipid and atherosclerosis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
34 |
IL6
| 20件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Malaria, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis, Lipid and atherosclerosis | D08976
D08976
|
Pomalidomide
| 6件: 28 28, 34, 51, 85, 227, 331 |
35 |
IL6
| 20件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Malaria, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis, Lipid and atherosclerosis | D09669
D09669
|
Siltuximab
| 2件: 28 28, 331 |
36 |
IL6
| 20件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Malaria, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis, Lipid and atherosclerosis | D10080
D10080
|
Sirukumab
| 2件: 41 41, 46 |
37 |
IL12A
| 11件: Toll-like receptor signaling pathway Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Type I diabetes mellitus, Pertussis, Malaria, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis | D09214
D09214
|
Ustekinumab
| 17件: 37 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
38 |
IL12B
| 11件: Toll-like receptor signaling pathway Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Type I diabetes mellitus, Pertussis, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Proteoglycans in cancer, Lipid and atherosclerosis | D09214
D09214
|
Ustekinumab
| 17件: 37 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
39 |
JAK2
| 11件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09959
D09959
|
Ruxolitinib
| 1件: 228 228 |
40 |
JAK2
| 11件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09970
D09970
|
Tofacitinib
| 15件: 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 |
41 |
JAK2
| 11件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D10308
D10308
|
Baricitinib
| 13件: 41 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 |
42 |
JAK2
| 11件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D10653
D10653
|
Peficitinib
| 1件: 46 46 |
43 |
MAP3K5
| 13件: Platinum drug resistance Platinum drug resistance, MAPK signaling pathway, Sphingolipid signaling pathway, Protein processing in endoplasmic reticulum, Tight junction, TNF signaling pathway, Thermogenesis, Neurotrophin signaling pathway, Non-alcoholic fatty liver disease, Parkinson disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Lipid and atherosclerosis | D10988
D10988
|
Selonsertib
| 1件: 86 86 |
44 |
NFE2L2
| 4件: Protein processing in endoplasmic reticulum Protein processing in endoplasmic reticulum, Parkinson disease, Pathways in cancer, Lipid and atherosclerosis | D10964
D10964
|
Omaveloxolone
| 1件: 18 18 |
45 |
NFKB1
| 37件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, NF-kappa B signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D01146
D01146
|
Iguratimod
| 4件: 46 46, 51, 53, 271 |
46 |
PIK3CA
| 47件: Metabolic pathways Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D11158
D11158
|
Leniolisib
| 2件: 53 53, 65 |
47 |
PIK3CB
| 47件: Metabolic pathways Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D11158
D11158
|
Leniolisib
| 2件: 53 53, 65 |
48 |
PIK3CD
| 47件: Metabolic pathways Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D11158
D11158
|
Leniolisib
| 2件: 53 53, 65 |
49 |
PIK3CD
| 47件: Metabolic pathways Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D11437
D11437
|
Parsaclisib
| 3件: 35 35, 53, 61 |
50 |
PPARG
| 9件: PPAR signaling pathway PPAR signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis | D00596
D00596
|
Rosiglitazone
| 5件: 46 46, 75, 97, 222, 265 |
51 |
PPARG
| 9件: PPAR signaling pathway PPAR signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis | D00945
D00945
|
Pioglitazone
| 17件: 2 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
52 |
PPARG
| 9件: PPAR signaling pathway PPAR signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis | D08378
D08378
|
Pioglitazone
| 17件: 2 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
53 |
PPARG
| 9件: PPAR signaling pathway PPAR signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis | D08491
D08491
|
Rosiglitazone
| 5件: 46 46, 75, 97, 222, 265 |
54 |
PPARG
| 9件: PPAR signaling pathway PPAR signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis | D11256
D11256
|
Seladelpar
| 2件: 93 93, 94 |
55 |
PPARG
| 9件: PPAR signaling pathway PPAR signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis | D11603
D11603
|
Leriglitazone
| 1件: 20 20 |
56 |
PPP3CA
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
57 |
PPP3CA
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
58 |
PPP3CA
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
59 |
PPP3CA
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
60 |
PPP3CA
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09033
D09033
|
Voclosporin
| 1件: 222 222 |
61 |
PPP3CB
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
62 |
PPP3CB
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
63 |
PPP3CB
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
64 |
PPP3CB
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
65 |
PPP3CB
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09033
D09033
|
Voclosporin
| 1件: 222 222 |
66 |
PPP3CC
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
67 |
PPP3CC
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
68 |
PPP3CC
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
69 |
PPP3CC
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
70 |
PPP3CC
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09033
D09033
|
Voclosporin
| 1件: 222 222 |
71 |
PPP3R1
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
72 |
PPP3R1
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
73 |
PPP3R1
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
74 |
PPP3R1
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
75 |
PPP3R1
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09033
D09033
|
Voclosporin
| 1件: 222 222 |
76 |
PPP3R2
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
77 |
PPP3R2
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
78 |
PPP3R2
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
79 |
PPP3R2
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
80 |
PPP3R2
| 17件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09033
D09033
|
Voclosporin
| 1件: 222 222 |
81 |
MAPK11
| 35件: MAPK signaling pathway MAPK signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09639
D09639
|
Losmapimod
| 2件: 113 113, 222 |
82 |
MAPK11
| 35件: MAPK signaling pathway MAPK signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D10959
D10959
|
Neflamapimod
| 1件: 8 8 |
83 |
MAPK13
| 35件: MAPK signaling pathway MAPK signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09639
D09639
|
Losmapimod
| 2件: 113 113, 222 |
84 |
MAPK13
| 35件: MAPK signaling pathway MAPK signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D10959
D10959
|
Neflamapimod
| 1件: 8 8 |
85 |
BCL2
| 21件: Platinum drug resistance Platinum drug resistance, NF-kappa B signaling pathway, Sphingolipid signaling pathway, p53 signaling pathway, Protein processing in endoplasmic reticulum, PI3K-Akt signaling pathway, Necroptosis, NOD-like receptor signaling pathway, Neurotrophin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Shigellosis, Salmonella infection, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Small cell lung cancer, Lipid and atherosclerosis | D10679
D10679
|
Venetoclax
| 1件: 28 28 |
86 |
RELA
| 37件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Mitophagy - animal, PI3K-Akt signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D12181
D12181
|
Edasalonexent
| 1件: 113 113 |
87 |
RXRA
| 12件: PPAR signaling pathway PPAR signaling pathway, PI3K-Akt signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Lipid and atherosclerosis | D02754
D02754
|
Acitretin
| 1件: 37 37 |
88 |
RXRA
| 12件: PPAR signaling pathway PPAR signaling pathway, PI3K-Akt signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Lipid and atherosclerosis | D02815
D02815
|
Alitretinoin
| 1件: 49 49 |
89 |
RXRA
| 12件: PPAR signaling pathway PPAR signaling pathway, PI3K-Akt signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Lipid and atherosclerosis | D03106
D03106
|
Bexarotene
| 2件: 13 13, 75 |
90 |
RXRB
| 10件: PPAR signaling pathway PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Lipid and atherosclerosis | D02754
D02754
|
Acitretin
| 1件: 37 37 |
91 |
RXRB
| 10件: PPAR signaling pathway PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Lipid and atherosclerosis | D02815
D02815
|
Alitretinoin
| 1件: 49 49 |
92 |
RXRB
| 10件: PPAR signaling pathway PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Lipid and atherosclerosis | D03106
D03106
|
Bexarotene
| 2件: 13 13, 75 |
93 |
RXRG
| 10件: PPAR signaling pathway PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Lipid and atherosclerosis | D02754
D02754
|
Acitretin
| 1件: 37 37 |
94 |
RXRG
| 10件: PPAR signaling pathway PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Lipid and atherosclerosis | D02815
D02815
|
Alitretinoin
| 1件: 49 49 |
95 |
RXRG
| 10件: PPAR signaling pathway PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Lipid and atherosclerosis | D03106
D03106
|
Bexarotene
| 2件: 13 13, 75 |
96 |
MAPK12
| 35件: MAPK signaling pathway MAPK signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09639
D09639
|
Losmapimod
| 2件: 113 113, 222 |
97 |
MAPK12
| 35件: MAPK signaling pathway MAPK signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D10959
D10959
|
Neflamapimod
| 1件: 8 8 |
98 |
CCL2
| 7件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NOD-like receptor signaling pathway, TNF signaling pathway, Yersinia infection, Malaria, Rheumatoid arthritis, Lipid and atherosclerosis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
99 |
SRC
| 18件: Rap1 signaling pathway Rap1 signaling pathway, Mitophagy - animal, VEGF signaling pathway, Tight junction, Platelet activation, Neutrophil extracellular trap formation, Regulation of actin cytoskeleton, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Yersinia infection, Tuberculosis, Viral carcinogenesis, Proteoglycans in cancer, Lipid and atherosclerosis | D03252
D03252
|
Bosutinib
| 2件: 2 2, 67 |
100 |
SRC
| 18件: Rap1 signaling pathway Rap1 signaling pathway, Mitophagy - animal, VEGF signaling pathway, Tight junction, Platelet activation, Neutrophil extracellular trap formation, Regulation of actin cytoskeleton, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Yersinia infection, Tuberculosis, Viral carcinogenesis, Proteoglycans in cancer, Lipid and atherosclerosis | D03658
D03658
|
Dasatinib
| 2件: 51 51, 85 |
101 |
SRC
| 18件: Rap1 signaling pathway Rap1 signaling pathway, Mitophagy - animal, VEGF signaling pathway, Tight junction, Platelet activation, Neutrophil extracellular trap formation, Regulation of actin cytoskeleton, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Yersinia infection, Tuberculosis, Viral carcinogenesis, Proteoglycans in cancer, Lipid and atherosclerosis | D06414
D06414
|
Dasatinib
| 2件: 51 51, 85 |
102 |
SRC
| 18件: Rap1 signaling pathway Rap1 signaling pathway, Mitophagy - animal, VEGF signaling pathway, Tight junction, Platelet activation, Neutrophil extracellular trap formation, Regulation of actin cytoskeleton, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Yersinia infection, Tuberculosis, Viral carcinogenesis, Proteoglycans in cancer, Lipid and atherosclerosis | D09664
D09664
|
Saracatinib
| 3件: 6 6, 89, 272 |
103 |
TNF
| 31件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Malaria, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D00742
D00742
|
Etanercept
| 17件: 15 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298 |
104 |
TNF
| 31件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Malaria, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D00754
D00754
|
Thalidomide
| 20件: 2 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 |
105 |
TNF
| 31件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Malaria, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
106 |
TNF
| 31件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Malaria, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D02597
D02597
|
Adalimumab
| 18件: 19 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 |
107 |
TNF
| 31件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Malaria, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D02598
D02598
|
Infliximab
| 27件: 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
108 |
TNF
| 31件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Malaria, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D03441
D03441
|
Certolizumab pegol
| 8件: 37 37, 46, 49, 96, 97, 107, 226, 271 |
109 |
TNF
| 31件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Malaria, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D04358
D04358
|
Golimumab
| 8件: 46 46, 56, 84, 96, 97, 107, 270, 271 |
110 |
TNF
| 31件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Malaria, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D04687
D04687
|
Lenalidomide
| 8件: 16 16, 26, 28, 34, 49, 284, 300, 331 |
111 |
TNF
| 31件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Malaria, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D05393
D05393
|
Pegsunercept
| 1件: 46 46 |
112 |
TNF
| 31件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Malaria, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D08976
D08976
|
Pomalidomide
| 6件: 28 28, 34, 51, 85, 227, 331 |
113 |
TNF
| 31件: MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Malaria, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D09944
D09944
|
Ozoralizumab
| 1件: 46 46 |
114 |
CASP9
| 19件: Platinum drug resistance Platinum drug resistance, p53 signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Thyroid hormone signaling pathway, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, Viral myocarditis, Lipid and atherosclerosis | D11195
D11195
|
Rimiducid
| 6件: 19 19, 60, 65, 284, 285, 326 |
115 |
ROCK2
| 14件: Sphingolipid signaling pathway Sphingolipid signaling pathway, Vascular smooth muscle contraction, Wnt signaling pathway, Tight junction, Platelet activation, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Lipid and atherosclerosis | D07941
D07941
|
Fasudil
| 4件: 2 2, 5, 7, 51 |
116 |
ROCK2
| 14件: Sphingolipid signaling pathway Sphingolipid signaling pathway, Vascular smooth muscle contraction, Wnt signaling pathway, Tight junction, Platelet activation, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Lipid and atherosclerosis | D11815
D11815
|
Belumosudil
| 1件: 51 51 |
117 |
CD40
| 9件: NF-kappa B signaling pathway NF-kappa B signaling pathway, Toll-like receptor signaling pathway, Malaria, Toxoplasmosis, Transcriptional misregulation in cancer, Systemic lupus erythematosus, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis | D11357
D11357
|
Bleselumab
| 1件: 222 222 |
118 |
CD40
| 9件: NF-kappa B signaling pathway NF-kappa B signaling pathway, Toll-like receptor signaling pathway, Malaria, Toxoplasmosis, Transcriptional misregulation in cancer, Systemic lupus erythematosus, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis | D11597
D11597
|
Ravagalimab
| 2件: 53 53, 97 |
119 |
CD40
| 9件: NF-kappa B signaling pathway NF-kappa B signaling pathway, Toll-like receptor signaling pathway, Malaria, Toxoplasmosis, Transcriptional misregulation in cancer, Systemic lupus erythematosus, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis | D11610
D11610
|
Iscalimab
| 2件: 49 49, 53 |
120 |
CD40LG
| 8件: NF-kappa B signaling pathway NF-kappa B signaling pathway, T cell receptor signaling pathway, Malaria, Toxoplasmosis, Systemic lupus erythematosus, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis | D06193
D06193
|
Toralizumab
| 1件: 63 63 |